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Summary
QUESTIONS UNDER STUDY: The impact of assisted re-
productive technology (ART) on Swiss demography was
quantified. From 1993 to 2012 the number of deliveries, in-
cluding multiples, generated by ART was compared with
overall delivery numbers. Swiss experts in ART collabor-
ated in a consensus to increase successful outcomes, to re-
duce the incidence of complications of ART and to valid-
ate recommendations through statistical review of available
data.
METHODS: Data generated between 1993 and 2012 and
published by the Federal Office of Statistics (BfS) were
compared with the Swiss database on ART (FIVNAT-CH)
as organised by the Swiss Society of Reproductive Medi-
cine (SGRM). From these analyses a panel of Swiss experts
in ART extracted recommendations to improve current
practice, to prevent complications related to ART and to re-
commend changes in current Swiss legislation dealing with
ART.
RESULTS: Since 1993 the age of women giving birth rose
together with the number of women asking for ART. This
demographic trend was reflected in a rise in the number
of deliveries generated by ART (in 2012: 2.2%) and the
proportion of multiple births (in 2012: 17.6%). The out-
come of ART was most negatively influenced by the age of
the treated patient. The number of retrieved oocytes decis-
ively impacted the likelihood of delivery, the risk of mul-
tiple births and the incidence of ovarian hyperstimulation
syndrome.
CONCLUSIONS: Optimal ovarian stimulation should be
designed for the retrieval of 10 to 15 oocytes per treatment.
Swiss legislation should enable and stimulate a policy of
elective single embryo transfer to avoid multiple births.
Key words: assisted reproductive technology;
demography; multiple births; controlled ovarian
hyperstimulation; AMH
Introduction
At all ages and in all societies infertility has constituted a
major health problem. Its incidence is currently thought to
be on the rise due to the increasing age of women at child-
birth and sequential family planning. As a result of these
demographic trends, the demand for medical support is
similarly growing, as demonstrated by the widening variety
of supporting treatment modalities to alleviate infertility
[1]. In addition to conventional in vitro fertilization (IVF)
and intracytoplasmic sperm injection (ICSI), the techno-
logy of cryopreservation of gametes and embryos has been
improved to such extent that oocytes can now be stored
frozen, allowing long term deferral of conception. This
strategy may become particularly helpful to young women
afflicted by malignant diseases requiring chemotherapy or
radiation potentially destructive to their ovaries [2]. For
women whose ovarian reserve has declined irreversibly
due to ageing or disease, oocytes donated by younger wo-
men have now been established as a safe treatment for both
donors and acceptors. Transmission of genetic disease to
the offspring can be prevented in affected families by the
use of preimplantation genetic diagnostics (PGD) or re-
duced through the sorting of spermatozoa [3]. Both mul-
tiple deliveries and OHSS are the most common complica-
tions of ART and are associated with high morbidity rates
and significant financial burden. Along with the develop-
ment of new technologies in ART, hormonal stimulation of
ovaries has been refined so that premature ovulation as well
as OHSS can now be avoided. The elective transfer of one
single high quality embryo (eSET) displaying the highest
developmental potential has considerably reduced multiple
pregnancy rates in various countries [4–6].
In Switzerland the adoption of many of these developments
has been hampered by a restrictive and outdated legislation
[7], which has been in effect since January 2001 [8] and
has remained unchanged since then. Currently, PGD, oo-
cyte donation and the cryopreservation of embryos are pro-
hibited. The number of pronucleate oocytes that may be
cultured to the embryonic stage is limited to three. If more
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than three pronucleate oocytes are available, these must be
stored frozen at the pronucleate stage, not at the embryonic
stage. The consequences of these legal restrictions are man-
ifold. On the one hand, a rising number of infertile couples
seek treatment in surrounding countries; on the other hand,
ART continues to induce a variety of otherwise preventable
complications, such as the birth of multiples [9] and OHSS.
Despite these restrictions, ART has thrived in Switzerland
and is now well embedded in Swiss society. In 1993 the
Swiss medical community involved in ART established a
central data register that collects detailed information and
outcome data of all ART-procedures carried out in Switzer-
land [10]. This data is transmitted to the Federal Office of
Statistics (BfS) in Neuchâtel, to the European IVF-Monit-
oring Consortium (EIM) of the European Society of Repro-
duction and Human Embryology (ESHRE) and to the Inter-
national Committee for Monitoring Assisted Reproductive
Technology (ICMART). In Europe, Switzerland belongs
to the few countries with complete follow up of all ART
data including those of all neonates arising from ART in
Switzerland. In response to politicians and lay persons still
critical of ART the setting up and pursuing of this registry
was motivated by the desire to add transparency to the
activities of the Swiss institutions involved in ART.
Twenty years after the initial foundation of FIVNAT-CH a
working group of leading experts in ART in Switzerland
was assembled over a period of two years to analyse data
and to formulate recommendations.
Material and methods
Data collection
As described earlier [10], data concerning the medical in-
dication for embarking on treatment with ART in both the
female and male partners were required, together with de-
tails on the treatment protocols for controlled ovarian hy-
perstimulation, oocyte collection, mode of ART, embryo
transfer and luteal support. In addition, information on
cryopreservation and thawing of oocytes at the pronucleate
stage and embryos was collected together with outcome
data including pregnancy, mode of delivery and neonate
condition.
Data collection was anonymous, but all reports were iden-
tified by a registration number given to each participating
institution and by an additional identification number given
by the institution to each individual couple. The couple’s
identification number remained unmodified during re-
peated treatments in each participating centre. For each
treatment cycle started, the centre reported the required
data, originally in paper, later by email. The data was re-
ported twice a year to the central office of FIVNAT-CH
as treatment data and delivery data were collected separ-
ately. The central office verified all incoming data and in-
formed the participating institutions if data were missing or
inconsistent. A report was presented during annual meet-
ings of all participating institutions, in which means and
trends were evaluated statistically for each institution in
comparison to the overall Swiss data. All annual reports
were continuously published on the internet website of the
Swiss Society of Reproductive Medicine (www.sgrm.org).
The quality of data reporting was additionally verified by
external audits, which were repeated every second year.
The external audits were carried out by internationally well
known experts, who checked the consistency of a randomly
selected set of treatments and a randomly selected set of
reported outcome data. They also compared the complete-
ness of the entire reported data set with the local data set.
For each audited centre an individual report was written,
in which the number of errors in each institution was com-
pared with the others and over time.
Data analysis and statistics
Overall demographic data of Switzerland were extracted
from a public data base constructed and presented by the
Swiss Federal Office of Statistics (BfS, www.bfs.ch). Dur-
ing the time interval spanning 1993 to 2012 the following
data sets were downloaded: female age at delivery, overall
number of deliveries per year, number of singleton deliver-
ies and number of multiple deliveries per year, incidence of
OHSS and number of cancelled treatments.
The data dealing with ART was extracted from the
FIVNAT-CH data base by a professional statistician. For
all analyses the data of all participating institutions were
pooled. Whereas overall outcome data were available since
1993, for detailed analyses the data collected between 2005
and 2012 was combined together. The following outcome
A
B
Figure 1
A Age of women giving birth in Switzerland between 1993 and
2012 was extracted from the data base constructed and published
by the Swiss Federal Office of Statistics (BfS). During this
observation period the proportion of women giving birth at the age
of 35 to 39 years or older has nearly doubled, whereas the age of
women giving birth at the age of 40 years or older has risen more
than threefold.
B During the observation period between 1993 and 2012 the
number of treatments with ART, including IVF, ICSI and the transfer
of frozen/thawed embryos and oocytes at the pronucleate stage,
has risen almost continuously, as evidenced by the Swiss ART data
registry, FIVNAT-CH.
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parameters were considered: overall number of single and
multiple deliveries, the number of single and multiple de-
liveries after ART, the number of cases with OHSS. For
each of these outcome parameters a graphical display with
the crude outcome data was given. In addition, differences
in the presence or absence of (multiple) deliveries were
compared among populations and presented by their odds
ratios ± 95% confidence intervals. All differences were as-
sessed using Chi-squared analysis and the Fisher’s exact
test. A p-value <0.05 was considered statistically signific-
ant.
Results
Relationship of ART to changing demands in
Switzerland
Since 1993 the proportion of Swiss women giving birth at
the age of 35 to 39 years or older nearly doubled, whereas
the number of women giving birth at the age of 40 years
or older more than tripled to 6% in 2012 (fig. 1A). In par-
allel, the number of women younger than 30 years giving
birth diminished from approximately 50% in 1993 to ap-
proximately 33% in 2012. This ongoing demographic trend
is accompanied by an almost steadily increasing number of
treatments with ART (fig. 1B).
A
B
Figure 2
A By putting together the number of all deliveries and the overall
number of multiple deliveries (given by the BfS) and the number of
deliveries and multiple deliveries after ART (recorded by FIVNAT-
CH), the number of births and multiple births generated by ART can
be compared with the overall birth data in Switzerland. Since 1993
both the absolute number of births generated by ART and the
absolute number of multiple deliveries, mostly of twins, have been
rising continuously.
B Since 1993, the proportion of births generated by ART has been
rising almost continuously, so that in 2012 2.2% of all deliveries in
Switzerland were originated by ART. In addition, the proportion of
multiple deliveries generated by ART has risen to 17.6% of all
multiple births in Switzerland in 2012.
Contribution of ART to multiple births in Switzerland
Since the first establishment of the FIVNAT-CH data re-
gistry in 1993 the absolute number of live births achieved
with ART increased nearly constantly (fig. 2A), so that now
the proportion of births after ART is approximating 2.2%
of all births registered in Switzerland (fig. 2B). Along with
the absolute number of deliveries, the absolute number of
multiple births rose (fig. 2A). Twin deliveries increasingly
contribute to the bulk of multiple births as their numbers
rose from 956 in 1993 (1.14%) to 1,559 (1.49%) in 2012.
During the same time interval the number of twin deliveries
induced by ART and recorded by FIVNAT-CH rose from
28 (2.9% of all twin deliveries) in 1993 to 259 (16.6% of all
twin deliveries) in 2012. Therefore, the proportion of mul-
tiple deliveries induced by ART increased to a much larger
extent than those occurring naturally and now accounts for
almost 20% of all multiple births in Switzerland (fig. 2B).
A
B
Figure 3
A The yearly delivery rates per embryo transfer (in %) achieved
with ART from 2005 to 2012 were computed in relation to the
number of collected oocytes and to the age of the infertile women
during the treatment. The outcome of ART strongly depends on the
age of the treated patient and to a lesser extent on the number of
collected oocytes.
B Delivery rates and their relationship with the number of collected
oocytes and the age of the treated infertile women at oocyte
collection, using the pooled FIVNAT-CH data collected between
2005 and 2012. Among all treated patients the delivery rates per
embryo transfer significantly depended on the quantity of retrieved
oocytes (p <0.0001), but this dependence was less pronounced
among younger patients. In each age category the number of
deliveries was significantly lower if fewer than five oocytes were
retrieved. In all age categories (except those older than 39 years)
the delivery rates were not further improved if more than 15 oocytes
were collected.
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Relationship between the number of collected oocytes
in ART and the likelihood of successful delivery
The yearly delivery rates per embryo transfer (in %)
achieved with ART from 2005 to 2012 were computed in
relation to the number of collected oocytes and to the age of
the infertile women during the treatment (fig. 3A). Where-
as the delivery rates were generally lower among women
aged 35 years or more (2,727 births after 18,757 embryo
transfers, 14.5%) as compared to those younger than 35
years (3,068 births after 11,842 embryo transfers, 25.9%),
the delivery rates did not vary much among age categor-
ies of women younger than 35 years. Among all treated pa-
tients the delivery rates per embryo transfer significantly
depended on the quantity of retrieved oocytes (p <0.0001),
but this dependence was less pronounced among young-
er patients (fig. 3B). In addition, in each age category the
number of deliveries was lower in cases where fewer than
five oocytes have been retrieved. In all categories (except
those older than 39 years) the delivery rates were not fur-
ther improved if more than 15 oocytes had been collected
(fig. 3B).
Relationship between the number of oocytes collected
and the incidence of multiple births and of OHSS
The most severe complications of ART are multiple gest-
ations and OHSS. The yearly proportion (in %) of twin,
triplet and quadruplet deliveries per treatment cycle with
ART (including both fresh and thawing cycles) between
2005 and 2012 together with the proportion of OHSS per
freshly stimulated treatment cycles (in %) is depicted in
figure 4. Whereas the number of multiple births has re-
mained constant over this observation period, the incidence
of OHSS dropped from 3.6% in 2005 to 1.0% in 2012.
In figure 5A the relationship between the number of re-
trieved oocytes, the mean age of the treated patients during
oocyte collection and the incidence of multiple deliveries is
assessed during the observation period from 2005 to 2012.
Whereas the incidence of multiple deliveries per embryo
transfer was lower among women aged 35 years or older
(432 multiple births after 2,707 embryo transfers, 16.0%)
Figure 4
The yearly proportion (%) of twin, triplet and quadruplet deliveries
per treatment cycle with ART (including both fresh and thawing
cycles) and the proportion of OHSS per freshly stimulated
treatment cycles (in %) was calculated from the pooled FIVNAT-CH
data collected between 2005 and 2012. While the number of
multiple births has remained constant, the incidence of OHSS
dropped from 3.6% 1.0%.
than women younger than 35 years (719 multiple births
after 3,049 embryo transfers, 23.6%), the incidence of mul-
tiple deliveries significantly depended on the age of the
treated patient (p <0.0001) and was lower, if fewer than
five or ten oocytes were retrieved. The incidence of mul-
tiple deliveries was unrelated to the number of retrieved oo-
cytes in women younger than 30 years (fig. 5B).
The incidence of OHSS per initiated controlled ovarian hy-
perstimulation (in %, fig. 6A) and per embryo transfer (in
%, fig. 6C) from 2005 to 2012 was computed in relation
to the number of collected oocytes and the age of the in-
fertile patients. We also computed the cancellation rate per
initiated treatment cycle (fig. 6B). The incidence of OHSS
rose significantly if more than 14 oocytes were collected,
regardless of the age of the patient. Among all age groups,
17.8% of all initiated treatment cycles embryo transfers
were cancelled, if fewer than five but, more frequently, if
19 or more oocytes had been collected (14.5% in women
A
B
Figure 5
A Using the pooled FIVNAT-CH data, the relationship between the
number of retrieved oocytes, the mean age of the treated patients
at oocyte collection and the incidence of multiple deliveries was
assessed during the observation period from 2005 to 2012. The
incidence of multiple deliveries most strongly depended on the age
of the treated women and to a lesser extent on the number of
collected oocytes.
B Number of multiple deliveries and its relationship with the number
of collected oocytes and the age of the treated infertile women at
oocyte collection, using the pooled FIVNAT-CH data collected
between 2005 and 2012. Whereas the incidence of multiple
deliveries per embryo transfer was generally lower among women
aged 35 years or older, the incidence of multiple deliveries was very
significantly age dependent (p <0.0001) and was lower if fewer than
five or ten oocytes had been retrieved. Among women younger
than 30 years the incidence of multiple deliveries was not related to
the number of retrieved oocytes.
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older than 35 years and 20.1% in women younger than 30
years, fig. 6B).
Discussion
Despite a restrictive legal framework ART has been thriv-
ing in Switzerland, as evidenced by the continuous rise of
A
B
C
Figures 6
A‒C The incidence of OHSS per initiated controlled ovarian
hyperstimulation (in %, panel A), the cancellation rate per initiated
cycle and the incidence of OHSS per embryo transfer (in %, panel
C) taken from the pooled FIVNAT-CH data collected between 2005
to 2012 were computed in relationship to the number of collected
oocytes and the age of the treated infertile patients. The incidence
of OHSS rises significantly if more than 14 oocytes are collected. In
17.8% of all treatment cycles in which 19 or more oocytes were
collected embryo transfer was cancelled to avoid OHSS. Among all
age groups, the cancellation rate was the highest when fewer than
five oocytes or 19 or more oocytes were collected (panel B).
the number of treatments. As a result of this development,
the proportion of newborns achieved with ART has now
reached 2.2% of all newborns.
Nonetheless, we face several major challenges in ART.
Firstly, the age of women seeking ART is constantly rising,
which requires personalised and adequate diagnostics and
treatment modalities in order to achieve an acceptable out-
come. Secondly, the proportion of multiple deliveries has
increased disproportionately and ART is now responsible
for almost 20% of all multiple births in Switzerland. In the
present data set, even in women aged 39 years or more,
multiple delivery rates are around 10%, which in this age
category is considered high due to the associated signific-
ant adverse effects. Thirdly, OHSS has now become a pre-
ventable complication of ART and should be avoided ac-
cordingly.
Concerned with these issues, a panel of Swiss experts in
ART was assembled to elaborate a consensus to increase
successful outcome as well as to reduce the incidence of
complications of ART and validate these through a statist-
ical review of the Swiss data (FIVNAT-CH data registry
2005–2012).
The results of this review clearly demonstrate the age de-
pendency of both the delivery and the multiple delivery
rates after embryo transfer (fig. 3B and 5B). In addition,
among women aged 30 years or more, the delivery rate is
significantly lower if fewer than five or ten oocytes are re-
trieved. In most age categories the likelihood of a healthy
pregnancy and delivery is not enhanced if more than 15 oo-
cytes are collected. These findings confirm earlier findings
in a large cohort of women in the U.K. [11]. The incidence
of multiple delivery also correlates both with the age of the
patient and the number of retrieved oocytes. Except in wo-
men younger than 30 years, the incidence of multiple de-
liveries is significantly lower, if fewer than ten oocytes are
collected (fig. 5B), whereas the risk of OHSS rises in all
age categories, if more than 14 oocytes are collected (fig.
6A and B).
Based on these findings, the panel concluded that ovarian
stimulation should optimally be designed for the retrieval
of 10 to 15 oocytes per treatment cycle. This number of oo-
cytes is associated with the presence of good quality em-
bryos available for embryo transfer but also for the avail-
ability of a fair number of pronucleate oocytes for cryop-
reservation.
As the potency of an individual woman’s ovaries to re-
spond to the ovarian stimulation regimen is highly variable,
the panel focused on methods to predict the outcome of
controlled ovarian hyperstimulation. Among all available
measurements of ovarian reserve, such as the antral follicle
count (AFC), the basal FSH concentration and early fol-
licular phase inhibin B concentration, the serum concen-
tration of the anti-Muellerian hormone (AMH) has been
shown to correlate best with the number of retrieved oo-
cytes [12–16]. In addition, the AMH serum levels are also
helpful for the prediction of low ovarian response as well
as of the risk of OHSS [17–18]. A single AMH serum value
may guide treatment up to 12 months both for the pre-
diction of poor and excessive ovarian response. However,
AMH as one single parameter set alone may not be reliable
enough to predict the quality of the oocytes and therefore
Original article Swiss Med Wkly. 2015;145:w14087
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the final outcome of IVF. As the conditions for the col-
lection of an adequate number of oocytes vary with age,
the most adapted gonadotropin dosage should be selected
based on age, the AMH serum level and possibly additional
parameters. A number of algorithms have been constructed
and validated for this purpose, such as the PIVET al-
gorithm [19] and the CONSORT algorithm [20]. Few al-
gorithms have yet been proposed based on AMH [21–23]
and large, prospective, multicentre studies are now needed
to validate existing nomograms.
Based on these studies the panel concluded that AMH on
its own is only of limited value to estimate prospective
ovarian response and to reduce the risk of OHSS and that
AFC should always be included in the calculation of the ex-
pected number of oocytes. Poor assay reproducibility may
also account for the limited predictive value of AMH to
date [24].
In addition to the fine tuning of the most appropriate dose
of gonadotropins to the number of oocytes to be retrieved
based on AMH and AFC, the expert panel also recommen-
ded the use of GnRH-antagonist based stimulation proto-
cols, as these have been shown to be associated with a sig-
nificantly lower risk of OHSS despite similar outcome data
as compared to the long GnRH-agonistic protocol [25]. The
GnRH-antagonistic protocol also offers the opportunity to
induce the final maturation of the oocyte with a GnRH-ag-
onist (a process denominated «triggering») thereby avoid-
ing the administration of human chorionic gonadotropin.
This helps to avoid the occurrence of OHSS, but necessit-
ates the cryopreservation of all oocytes or oocytes at the
pronucleate stage. This freeze-all strategy, demonstrated to
be highly effective for the prevention of OHSS in a pro-
spective multicentre study [26], is already widely used by
the members of FIVNAT-CH (fig. 6B).
In addition, the expert panel concluded that there is cur-
rently no evidence for the superiority of any protocol of
ovarian hyperstimulation (short GnRH-agonist, long
GnRH-agonist, GnRH-antagonist) with respect to the out-
come in low ovarian responders. The incidence of natural
cycle IVF in low responders is on the rise, although recent
data suggests that it does not benefit genuine poor ovarian
responders [27]. Finally, the expert panel concluded that
there should be no lower limit for the number of follicles
aspirated.
Whereas in neighbouring countries the policy of replacing
one single embryo selected from a cohort of embryos is in-
creasingly contributing to a lower incidence of multiple de-
livery [4–6], the current legal ban on cryopreservation of
embryos (except in an emergency situation) and the lack
of embryo selection prohibits all progress in this direction
[28]. An adaptation of the current restrictive Swiss legis-
lation is urgently required to facilitate the impressive pro-
gress in reproductive medicine. This will allow a signific-
ant reduction of the major and steadily increasing problem
of multiple pregnancies imposing unnecessary health risks
and financial burden to Swiss society.
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A
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Figure 1
A Age of women giving birth in Switzerland between 1993 and 2012 was extracted from the data base constructed and published by the Swiss
Federal Office of Statistics (BfS). During this observation period the proportion of women giving birth at the age of 35 to 39 years or older has
nearly doubled, whereas the age of women giving birth at the age of 40 years or older has risen more than threefold.
B During the observation period between 1993 and 2012 the number of treatments with ART, including IVF, ICSI and the transfer of frozen/
thawed embryos and oocytes at the pronucleate stage, has risen almost continuously, as evidenced by the Swiss ART data registry, FIVNAT-
CH.
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Figure 2
A By putting together the number of all deliveries and the overall number of multiple deliveries (given by the BfS) and the number of deliveries
and multiple deliveries after ART (recorded by FIVNAT-CH), the number of births and multiple births generated by ART can be compared with
the overall birth data in Switzerland. Since 1993 both the absolute number of births generated by ART and the absolute number of multiple
deliveries, mostly of twins, have been rising continuously.
B Since 1993, the proportion of births generated by ART has been rising almost continuously, so that in 2012 2.2% of all deliveries in
Switzerland were originated by ART. In addition, the proportion of multiple deliveries generated by ART has risen to 17.6% of all multiple births
in Switzerland in 2012.
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Figure 3
A The yearly delivery rates per embryo transfer (in %) achieved with ART from 2005 to 2012 were computed in relation to the number of
collected oocytes and to the age of the infertile women during the treatment. The outcome of ART strongly depends on the age of the treated
patient and to a lesser extent on the number of collected oocytes.
B Delivery rates and their relationship with the number of collected oocytes and the age of the treated infertile women at oocyte collection, using
the pooled FIVNAT-CH data collected between 2005 and 2012. Among all treated patients the delivery rates per embryo transfer significantly
depended on the quantity of retrieved oocytes (p <0.0001), but this dependence was less pronounced among younger patients. In each age
category the number of deliveries was significantly lower if fewer than five oocytes were retrieved. In all age categories (except those older than
39 years) the delivery rates were not further improved if more than 15 oocytes were collected.
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Figure 4
The yearly proportion (%) of twin, triplet and quadruplet deliveries per treatment cycle with ART (including both fresh and thawing cycles) and
the proportion of OHSS per freshly stimulated treatment cycles (in %) was calculated from the pooled FIVNAT-CH data collected between 2005
and 2012. While the number of multiple births has remained constant, the incidence of OHSS dropped from 3.6% 1.0%.
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Figure 5
A Using the pooled FIVNAT-CH data, the relationship between the number of retrieved oocytes, the mean age of the treated patients at oocyte
collection and the incidence of multiple deliveries was assessed during the observation period from 2005 to 2012. The incidence of multiple
deliveries most strongly depended on the age of the treated women and to a lesser extent on the number of collected oocytes.
B Number of multiple deliveries and its relationship with the number of collected oocytes and the age of the treated infertile women at oocyte
collection, using the pooled FIVNAT-CH data collected between 2005 and 2012. Whereas the incidence of multiple deliveries per embryo
transfer was generally lower among women aged 35 years or older, the incidence of multiple deliveries was very significantly age dependent (p
<0.0001) and was lower if fewer than five or ten oocytes had been retrieved. Among women younger than 30 years the incidence of multiple
deliveries was not related to the number of retrieved oocytes.
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Figures 6
A‒C The incidence of OHSS per initiated controlled ovarian hyperstimulation (in %, panel A), the cancellation rate per initiated cycle and the
incidence of OHSS per embryo transfer (in %, panel C) taken from the pooled FIVNAT-CH data collected between 2005 to 2012 were computed
in relationship to the number of collected oocytes and the age of the treated infertile patients. The incidence of OHSS rises significantly if more
than 14 oocytes are collected. In 17.8% of all treatment cycles in which 19 or more oocytes were collected embryo transfer was cancelled to
avoid OHSS. Among all age groups, the cancellation rate was the highest when fewer than five oocytes or 19 or more oocytes were collected
(panel B).
Original article Swiss Med Wkly. 2015;145:w14087
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 13 of 13
